ARWR
Arrowhead Pharmaceuticals, Inc.
$71.91
-2.20 (-2.97%)
At close · Jul 14
Market Cap
$10.13B
Shares
140,857,021
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-06-16 | 2026-06-12 | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| Investor Event Transcript | 2026-03-31 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| 8-K | 2026-03-20 | 2026-03-19 | |
| 10-Q | 2026-02-05 | 2025-12-31 | |
| 8-K | 2026-02-05 | — | |
| DEF 14A | 2026-01-27 | 2026-01-26 | |
| 8-K | 2026-01-12 | — | |
| 8-K | 2026-01-09 | 2026-01-07 | |
| 8-K | 2026-01-06 | — | |
| 8-K | 2025-11-25 | — | |
| 10-K | 2025-11-25 | 2025-09-30 | |
| 8-K | 2025-11-18 | — | |
| 10-K/A | 2025-10-10 | 2024-09-30 | |
| 8-K | 2025-09-12 | 2025-09-11 | |
| 8-K | 2025-09-11 | 2025-09-10 | |
| 8-K | 2025-09-02 | — | |
| 8-K | 2025-08-07 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 10-Q | 2025-05-12 | 2025-03-31 | |
| 8-K | 2025-05-12 | — | |
| 8-K | 2025-04-15 | 2025-04-11 | |
| 8-K | 2025-03-19 | 2025-03-12 | |
| 8-K | 2025-02-10 | — | |
| 10-Q | 2025-02-10 | 2024-12-31 | |
| 8-K | 2025-02-07 | — | |
| DEF 14A | 2025-01-29 | 2025-01-28 | |
| 8-K | 2024-12-18 | 2024-12-11 | |
| 8-K | 2024-11-26 | — | |
| 10-K | 2024-11-26 | 2024-09-30 | |
| 8-K | 2024-08-08 | — | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-05-09 | — | |
| 10-Q | 2024-05-09 | 2024-03-31 | |
| 8-K | 2024-03-19 | 2024-03-14 | |
| 8-K/A | 2024-03-18 | 2024-02-21 | |
| 8-K | 2024-02-22 | 2024-02-21 | |
| 10-Q | 2024-02-06 | 2023-12-31 | |
| 8-K | 2024-02-06 | — | |
| DEF 14A | 2024-01-26 | — | |
| 8-K | 2024-01-22 | 2024-01-16 | |
| 8-K | 2024-01-04 | 2024-01-02 | |
| 8-K | 2023-12-05 | — | |
| 8-K | 2023-11-29 | — | |
| 10-K | 2023-11-29 | 2023-09-30 | |
| 10-Q | 2023-08-07 | 2023-06-30 | |
| 8-K | 2023-08-07 | — | |
| 8-K | 2023-05-02 | — |
Showing 1–50 of 103 filings
Key facts
CIK
879407
CUSIP
04280A100
13F (30d)
32 filings
27 filers
Visit website
Investor relations